Catalent Stock Price, News & Analysis (NYSE:CTLT)

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings or view top-rated stocks.

12 Wall Street analysts have issued 1-year target prices for Catalent's shares. Their CTLT share price targets range from $42.00 to $62.00. On average, they expect the company's stock price to reach $50.45 in the next twelve months. This suggests a possible upside of 33.0% from the stock's current price.
View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts.

Catalent's stock was trading at $45.01 at the beginning of the year. Since then, CTLT shares have decreased by 15.7% and is now trading at $37.95.
View the best growth stocks for 2023 here.

Catalent saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 10,700,000 shares, an increase of 5.9% from the October 31st total of 10,100,000 shares. Based on an average trading volume of 2,440,000 shares, the days-to-cover ratio is presently 4.4 days.
View Catalent's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our CTLT earnings forecast.

Catalent, Inc. (NYSE:CTLT) posted its earnings results on Wednesday, November, 15th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business earned $982 million during the quarter, compared to analyst estimates of $939.62 million. Catalent had a negative net margin of 22.36% and a positive trailing twelve-month return on equity of 1.54%. The company's quarterly revenue was down 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.25 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Catalent (NYSE:CTLT) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Biotechnology & Genome ETF (PBE), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH), Invesco S&P 500 Equal Weight Health Care ETF (RYH), Invesco S&P 500 Equal Weight Health Care ETF (RSPH) and WisdomTree BioRevolution Fund (WDNA).

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Catalent's stock is owned by a number of retail and institutional investors. Top institutional investors include Veritas Asset Management LLP (3.68%), Cadian Capital Management LP (2.94%), Barclays PLC (2.66%), Ameriprise Financial Inc. (1.93%), Invesco Ltd. (1.56%) and Morgan Stanley (1.24%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Charles Lickfold, Gregory T Lucier, John J Greisch, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michelle R Ryan, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph.
View institutional ownership trends.

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.